From Name:
From Email:
To Name:
To Email:

Optional Message:


FDA assessing data manipulation concerns with gene therapy product

from Pharmacy Times

Officials with the FDA issued a statement to clarify data accuracy issues with recently-approved gene therapy Zolgensma (onasemnogene abeparvovec-xioi, AveXis), a product intended to treat spinal muscular atrophy (SMA) in children under 2 years old. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063